Cargando…

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

OBJECTIVE: The aim of this meta‐analysis was to summarize the available results of immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based information for their potential predictive value of efficacy. METHODS: We searched PubMed, EMBASE, Web of Science, The Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lin‐Lu, Yu, Cheng‐Feng, Xie, Hong‐Ting, Chen, Zheng, Jia, Bo‐Hui, Xie, Fei‐Yu, Cai, Ya‐Fang, Xue, Peng, Zhu, Shi‐Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242871/ https://www.ncbi.nlm.nih.gov/pubmed/37161541 http://dx.doi.org/10.1002/cam4.5800

Ejemplares similares

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials
por: Li, Fei, et al.
Publicado: (2021)

YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
por: Li, Ling-Chen, et al.
Publicado: (2023)

Imaging-based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review
por: Pei, Xinyu, et al.
Publicado: (2023)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Mao, Xin-Cheng, et al.
Publicado: (2022)

Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Lee, Amy Junghyun, et al.
Publicado: (2021)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
por: Zhang, Zhening, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Alfranca, Yolanda Lage, et al.
Publicado: (2022)

Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
por: Takeuchi, Eiji, et al.
Publicado: (2023)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
por: von Itzstein, Mitchell S., et al.
Publicado: (2022)

Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment
por: Wang, Aoyun, et al.
Publicado: (2022)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2018)

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yu, Xiaolin, et al.
Publicado: (2021)

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hyojin, et al.
Publicado: (2022)

An analysis report on the application of immune checkpoint inhibitors after liver transplantation
por: Xie, Man, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data
por: Nie, Run-Cong, et al.
Publicado: (2021)

Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Costantini, Adrien, et al.
Publicado: (2020)

Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
por: Zhang, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ec5ntb2tkaucoik8pvcsv7thjb